Author:
Solomon Scott D.,Claggett Brian,Packer Milton,Desai Akshay,Zile Michael R.,Swedberg Karl,Rouleau Jean,Shi Victor,Lefkowitz Martin,McMurray John J.V.
Subject
Cardiology and Cardiovascular Medicine
Reference9 articles.
1. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure;Vardeny;J Am Coll Cardiol HF,2014
2. Angiotensin-neprilysin inhibition versus enalapril in heart failure;McMurray;N Engl J Med,2014
3. Effect of LCZ696, compared with enalapril, according to baseline risk in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF);Simpson;J Am Coll Cardiol,2015
4. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: the PARADIGM-HF trial;Solomon;Circ Heart Fail,2016
5. Murray A. PL Detail-Document, New Drug: Entresto (Sacubitril/Valsartan). Pharmacist’s Letter/Prescriber’s Letter. September 2015. Available at: http://prescribersletter.therapeuticresearch.com/pl/ArticlePDF.aspx?cs=&s=PRL&DocumentFileID=0&DetailID=310919&SegmentID=0%20usg=AFQjCNHlwDjwIfMoXThziRtRcxAQR0tlrg. Accessed May 26, 2016.
Cited by
96 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献